Neurology
Meningitis represents a critical medical emergency characterized by inflammation of the protective membranes covering the brain and spinal cord - the meninges. This condition spans a spectrum from self-limiting viral infections to rapidly fatal bacterial diseases requiring immediate intervention. Understanding meningitis pathophysiology, clinical presentation, and evidence-based management is essential for healthcare providers, as delayed diagnosis and treatment can lead to severe neurological sequelae or mortality within hours.
🦠 Meningitis Classification and Pathogens
Meningitis is classified based on causative organisms, clinical presentation, and cerebrospinal fluid characteristics, with bacterial meningitis representing the most urgent form requiring immediate antimicrobial therapy and supportive care.
Bacterial Meningitis
- Most common pathogens: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae
- Mortality: 10-30% despite appropriate antimicrobial therapy
- Clinical urgency: True medical emergency requiring immediate intervention
- Key CSF finding: High white blood cell count with neutrophilic predominance
- Pathophysiology: Bacterial invasion triggers intense inflammatory response with cytokine release
Viral Meningitis
- Most common pathogens: Enteroviruses, Herpes Simplex Virus, Varicella Zoster Virus
- Mortality: <1% (typically self-limited course)
- Clinical presentation: Generally milder, often without focal neurological deficits
- Key CSF finding: Lymphocytic predominance with normal glucose
- Epidemiology: Seasonal variation with enteroviruses peaking summer/fall
Other Meningitis Types
- Fungal meningitis: Cryptococcus (HIV-associated), Candida, Coccidioides
- Tuberculous meningitis: Subacute presentation, basilar predominance, high protein
- Parasitic meningitis: Amebic (Naegleria), eosinophilic meningitis (Angiostrongylus)
- Non-infectious causes: Drug-induced, autoimmune, carcinomatous, chemical
Pathophysiological Mechanisms
- Bacterial invasion: Hematogenous spread or direct extension from nearby infections
- Blood-brain barrier disruption: Increased permeability facilitates CNS entry
- Inflammatory cascade: Cytokine release (TNF-α, IL-1) causes meningeal inflammation
- Cerebral edema: Vasogenic and cytotoxic mechanisms contribute to increased ICP
- Neuronal injury: Direct bacterial toxicity and host inflammatory response
🎯 Clinical Memory Aid: Remember the classic triad of meningitis: Fever, Headache, Neck stiffness - but recognize it's only present in approximately 45% of bacterial meningitis cases! Jolt accentuation (head rotation worsening headache) has higher sensitivity (97%) for meningitis diagnosis.
👥 Age-Specific Pathogens and Epidemiology
The epidemiological profile and most likely causative organisms vary significantly by age group, immune status, and specific risk factors, guiding empiric antimicrobial selection and diagnostic considerations.
Common Pathogens by Age Group
| Age Group | Most Common Pathogens | Special Considerations | Empiric Antimicrobial Therapy |
|---|---|---|---|
| Neonates (<1 month) | Group B Streptococcus, Escherichia coli, Listeria monocytogenes | Maternal transmission, subtle non-specific presentation, immature immune system | Ampicillin + Cefotaxime/Ceftriaxone |
| Infants (1-3 months) | Group B Streptococcus, E. coli, Streptococcus pneumoniae | Transition period, still consider Listeria coverage, developing immunity | Ampicillin + Cefotaxime/Ceftriaxone |
| Children (3 months-18 years) | S. pneumoniae, N. meningitidis, H. influenzae type B | Vaccination impact significant, consider resistant S. pneumoniae | Vancomycin + Ceftriaxone/Cefotaxime |
| Adults (18-50 years) | S. pneumoniae, N. meningitidis | Consider risk factors (alcoholism, asplenia, complement deficiency) | Vancomycin + Ceftriaxone/Cefotaxime |
| Elderly (>50 years) & Immunocompromised | S. pneumoniae, Listeria monocytogenes, Gram-negative bacilli | Listeria monocytogenes important consideration, often healthcare-associated | Vancomycin + Ampicillin + Ceftriaxone/Cefotaxime |
Risk Factors and Epidemiological Considerations
Host Factors
- Complement deficiency: Increased susceptibility to Neisseria meningitidis
- Asplenia: Risk for encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis)
- CSF leak: Increased risk for S. pneumoniae meningitis
- Immunosuppression: Increased risk for Listeria, Cryptococcus, unusual pathogens
- Cochlear implants: Increased risk for pneumococcal meningitis
Environmental and Epidemiological Factors
- Close living quarters: Colleges, military barracks (meningococcal outbreaks)
- Seasonal variations: Enteroviruses (summer/fall), meningococcal (winter/spring)
- Geographic exposure: TB meningitis, fungal meningitis (specific endemic areas)
- Recent neurosurgery/trauma: Increased risk for staphylococcal, Gram-negative meningitis
- Travel history: Meningococcal belt (sub-Saharan Africa), coccidioidomycosis areas
⚠️ Clinical Pearl: Always consider Listeria monocytogenes in neonates, elderly (>50 years), pregnant women, and immunocompromised patients - it requires ampicillin coverage as it is inherently resistant to cephalosporins!
🩺 Clinical Presentation and Diagnosis
Early recognition relies on understanding the spectrum of clinical presentations across different age groups and host factors, with particular attention to subtle presentations in vulnerable populations.
Clinical Manifestations Across Age Groups
Classic Triad and Common Symptoms
- Fever: Present in 85-95% of bacterial meningitis cases
- Neck stiffness: Present in 70-80% (nuchal rigidity)
- Altered mental status: Present in 65-75% (confusion to coma)
- Headache: Present in 85-90% (often severe, global)
- Photophobia: Present in 30-50%
- Nausea/vomiting: Present in 35-75%
Special Considerations in Infants and Elderly
- Infant signs: Bulging fontanelle, high-pitched cry, poor feeding, lethargy/irritability
- Elderly presentation: Often subtle - confusion, lethargy without classic signs
- Immunocompromised: May lack fever or have attenuated inflammatory response
- Neonates: Hypothermia, jaundice, respiratory distress, seizures
Physical Examination Findings
| Sign | Technique | Interpretation | Sensitivity/Specificity |
|---|---|---|---|
| Kernig's Sign | Hip flexed to 90°, pain with knee extension | Suggests meningeal irritation and inflammation | 5% sensitive, 95% specific |
| Brudzinski's Sign | Neck flexion causes involuntary hip and knee flexion | Indicates meningeal irritation | 5% sensitive, 95% specific |
| Jolt Accentuation | Rapid head rotation 2-3 times/second worsens headache | Highly suggestive of meningitis when positive | 97% sensitive, 60% specific |
Meningococcal Rash and Systemic Manifestations
Meningococcal Rash Characteristics
- Appearance: Petechial or purpuric (non-blanching)
- Distribution: Can involve trunk, extremities, mucous membranes
- Progression: Rapid evolution, may coalesce into larger purpura
- Glass test: Positive (does not blanch with pressure)
- Clinical significance: Indicates meningococcemia with disseminated intravascular coagulation
Systemic Complications
- Septic shock: Vasodilation, capillary leak, myocardial depression
- Disseminated intravascular coagulation: Widespread microthrombi, bleeding
- Waterhouse-Friderichsen syndrome: Adrenal hemorrhage, refractory shock
- Multiorgan failure: Renal, respiratory, hepatic involvement
🚨 Emergency Alert: Don't wait for classic signs or diagnostic confirmation! In suspected bacterial meningitis, antibiotics should be administered within 30-60 minutes of presentation, even before neuroimaging or lumbar puncture if delays are anticipated. Time-to-antibiotics significantly impacts mortality and neurological outcomes.
🔬 Diagnostic Evaluation
A systematic diagnostic approach is essential, with lumbar puncture and cerebrospinal fluid analysis representing the cornerstone of meningitis diagnosis, supplemented by blood tests, imaging, and microbiological studies.
Lumbar Puncture and CSF Analysis
| Parameter | Normal Values | Bacterial Meningitis | Viral Meningitis | TB/Fungal Meningitis |
|---|---|---|---|---|
| Opening Pressure | 5-20 cm H2O | Elevated (>25 cm H2O) | Normal or slightly elevated | Markedly elevated (chronic cases) |
| White Blood Cell Count | 0-5 cells/μL | 100-10,000 cells/μL (neutrophil predominance) | 10-1000 cells/μL (lymphocyte predominance) | 10-1000 cells/μL (lymphocyte predominance) |
| Protein | 15-45 mg/dL | 100-500 mg/dL (markedly elevated) | Normal or slightly elevated | 100-500 mg/dL (very high in TB) |
| Glucose | 50-80 mg/dL (∼2/3 serum) | Low (<40 mg/dL) | Normal | Very low (especially TB) |
| CSF:Serum Glucose Ratio | >0.6 | <0.4 | >0.6 | <0.4 |
Additional Diagnostic Modalities
Microbiological Studies
- Gram stain: 60-90% sensitive in untreated bacterial meningitis
- Culture: Gold standard but requires 24-48 hours
- PCR: High sensitivity, rapid results, especially valuable with prior antibiotics
- Latex agglutination: Declining use but helpful for specific antigens
- CSF lactate: >4 mmol/L strongly suggests bacterial meningitis
Blood Tests and Imaging
- Blood cultures: Positive in 50-90% of bacterial meningitis cases
- Inflammatory markers: CRP, procalcitonin help distinguish bacterial vs viral
- CT head before LP: If altered mental status, focal deficit, immunocompromised, seizure, papilledema
- MRI with contrast: For complications assessment (empyema, abscess, venous thrombosis)
Partially Treated and Atypical Meningitis
Partially Treated Bacterial Meningitis
- Causes: Prior antibiotic administration, inadequate empiric coverage
- CSF pattern: May show lymphocytic predominance, culture often negative
- Diagnostic approach: PCR very helpful, clinical suspicion remains crucial
- Management: Continue broad-spectrum antibiotics, consider infectious diseases consultation
Chronic and Atypical Presentations
- TB meningitis: Subacute onset, cranial nerve palsies, basilar enhancement on MRI
- Fungal meningitis: Insidious onset, often immunocompromised host
- Chemical meningitis: Post-procedure, drug-induced, neoplastic meningitis
- Autoimmune meningitis: SLE, sarcoidosis, Behçet's disease
🔬 Clinical Insight: The CSF lactate level is particularly valuable in distinguishing bacterial from viral meningitis and remains reliable even with prior antibiotic administration. Levels >4 mmol/L strongly suggest bacterial meningitis with high specificity.
💊 Emergency Management and Treatment
Bacterial meningitis requires immediate, protocol-driven management with emphasis on rapid antimicrobial administration, adjunctive therapies, and comprehensive supportive care to optimize outcomes and minimize neurological sequelae.
Initial Emergency Management Protocol
| Intervention | Timing | Specific Details | Clinical Rationale |
|---|---|---|---|
| ABCs Assessment and Stabilization | Immediate (first 5 minutes) | Airway protection, oxygen administration, IV access, cardiac monitoring | Prevent hypoxia, secure vascular access for medications and fluids |
| Blood Cultures | Before antibiotic administration | 2 sets from different venipuncture sites, aerobic and anaerobic bottles | Maximize diagnostic yield before antibiotics sterilize blood |
| Empiric Antibiotic Therapy | Within 30-60 minutes of presentation | Based on age, risk factors, local resistance patterns | Time-critical intervention - each hour delay increases mortality |
| Dexamethasone Administration | With or before first antibiotic dose | 0.15 mg/kg q6h for 2-4 days (adults), 0.4 mg/kg q12h (children) | Reduce inflammatory sequelae, particularly hearing loss in pneumococcal meningitis |
| Fluid Resuscitation and Monitoring | Early and ongoing | Isotonic crystalloids, monitor for SIADH, maintain euvolemia | Correct hypovolemic shock while avoiding cerebral edema exacerbation |
Empiric Antimicrobial Therapy by Patient Group
| Patient Group | Empiric Antimicrobial Regimen | Special Considerations | Typical Duration |
|---|---|---|---|
| Neonates (0-1 month) | Ampicillin + Cefotaxime | Covers Listeria, Group B Streptococcus, Gram-negative organisms | 14-21 days based on organism and response |
| Infants and Children | Vancomycin + Ceftriaxone/Cefotaxime | Covers resistant S. pneumoniae, N. meningitidis, H. influenzae | 7-10 days (meningococcal), 10-14 days (pneumococcal) |
| Adults (18-50 years) | Vancomycin + Ceftriaxone/Cefotaxime | Add ampicillin if >50 years, immunocompromised, or alcohol use disorder | 7-21 days based on organism and clinical course |
| Elderly/Immunocompromised | Vancomycin + Ampicillin + Ceftriaxone/Cefotaxime | Must cover Listeria monocytogenes in these populations | 14-21 days, longer if complicated course |
| Post-neurosurgical/Trauma | Vancomycin + Cefepime/Meropenem | Cover Pseudomonas aeruginosa, MRSA, Gram-negative organisms | Variable based on organism and source control |
Adjunctive Therapies and Supportive Care
Dexamethasone Therapy
- Primary indication: Suspected or proven pneumococcal meningitis in adults
- Dosing: 0.15 mg/kg q6h for 2-4 days (10 mg q6h in adults)
- Timing: Administer with or before first antibiotic dose
- Benefit: Reduces hearing loss and neurological sequelae
- Controversies: Less clear benefit in meningococcal meningitis, variable pediatric data
Comprehensive Supportive Care
- Seizure management: Prophylaxis/treatment, EEG monitoring if altered mental status
- ICP management: Elevate head of bed, osmotherapy, hyperventilation if herniation
- Nutrition: Early enteral nutrition when stable, monitor for ileus
- Fever control: Antipyretics, cooling devices if needed
- Pain management: Appropriate analgesia for headache and meningismus
⚠️ Critical Point: Never delay antibiotics for imaging or lumbar puncture! If there will be any delay in performing these diagnostic procedures, administer antibiotics immediately after obtaining blood cultures. The mortality benefit of early antibiotics far outweighs the potential diagnostic uncertainty.
🦠 Specific Pathogen Management
Targeted antimicrobial therapy is guided by organism identification, susceptibility testing, and specific pathogen characteristics, with adjustments based on clinical response and complication development.
Pathogen-Directed Antimicrobial Therapy
| Organism | Preferred Therapy | Alternative Options | Duration | Special Considerations |
|---|---|---|---|---|
| Streptococcus pneumoniae | Vancomycin + Ceftriaxone | Meropenem, Moxifloxacin (if PCN allergic) | 10-14 days | Dexamethasone beneficial, check susceptibility testing |
| Neisseria meningitidis | Penicillin G or Ceftriaxone | Chloramphenicol, Meropenem | 7 days | Chemoprophylaxis for close contacts, report to public health |
| Group B Streptococcus | Ampicillin or Penicillin G | Ceftriaxone, Vancomycin (if PCN allergic) | 14-21 days | Common in neonates, maternal screening important for prevention |
| Listeria monocytogenes | Ampicillin + Gentamicin | Trimethoprim-sulfamethoxazole | 21 days or longer | Resistant to cephalosporins, important in specific risk groups |
| Haemophilus influenzae | Ceftriaxone | Chloramphenicol, Cefepime | 7-10 days | Rare due to vaccination, check β-lactamase production |
Viral and Atypical Meningitis Management
Viral Meningitis
- Most cases: Supportive care, analgesia, hydration
- HSV/VZV: IV Acyclovir (10-15 mg/kg q8h)
- HIV: Antiretroviral therapy initiation or optimization
- Enteroviruses: Typically self-limited (3-7 day course)
- Arboviruses: Supportive care, consider specific areas (West Nile, etc.)
Tuberculous Meningitis
- Initial regimen: 4-drug therapy (Isoniazid, Rifampin, Pyrazinamide, Ethambutol)
- Duration: 9-12 months total (2 months intensive phase)
- Adjunctive steroids: Dexamethasone reduces mortality
- Monitoring: Drug resistance testing, therapeutic drug monitoring
Fungal Meningitis
- Cryptococcus: Amphotericin B + Flucytosine induction
- Candida: Amphotericin B or high-dose Fluconazole
- Coccidioides: Fluconazole or Amphotericin B for severe cases
- Duration: Weeks to months depending on organism and immune status
🔬 Clinical Insight: Meningococcal disease has the most rapid progression - patients can deteriorate from completely well to death in less than 12 hours. Immediate antibiotic administration and aggressive supportive care are crucial, with particular attention to the development of purpura fulminans and Waterhouse-Friderichsen syndrome.
🛡️ Prevention and Public Health
Vaccination, chemoprophylaxis, and public health measures form the cornerstone of meningitis prevention, with significant reductions in disease incidence following implementation of comprehensive vaccination programs.
Vaccination Strategies and Schedules
| Vaccine | Target Pathogens | Recommended Populations | Schedule and Administration |
|---|---|---|---|
| PCV13/PPSV23 | Streptococcus pneumoniae (13/23 serotypes) | All children, adults >65 years, high-risk conditions | Childhood series (2,4,6,12-15 months), adult sequential administration |
| MenACWY | Neisseria meningitidis serogroups A,C,W,Y | Adolescents, college students, military, travelers to endemic areas | 11-12 years with booster at 16 years, high-risk every 5 years |
| MenB | Neisseria meningitidis serogroup B | High-risk individuals, outbreaks, adolescents/young adults (16-23) | 2-3 dose series depending on specific vaccine product |
| Hib | Haemophilus influenzae type B | All infants, high-risk older children and adults | Childhood series (2,4,6,12-15 months), dramatic incidence reduction |
Chemoprophylaxis and Infection Control
Chemoprophylaxis Indications
- Household contacts: Of meningococcal meningitis cases
- Direct exposure: To respiratory secretions of index case
- Daycare contacts: In same room as index case
- Airplane travelers: Seated directly next to case for prolonged flight
- Healthcare workers: Only if direct exposure to respiratory secretions
Chemoprophylaxis Regimens
- Rifampin: 600mg PO q12h × 2 days (adults), 10mg/kg q12h × 2 days (children)
- Ciprofloxacin: 500mg PO × 1 dose (adults), contraindicated in children
- Ceftriaxone: 250mg IM × 1 dose (all ages)
- Azithromycin: 10mg/kg × 1 dose (if strain sensitive)
Complications and Long-term Management
Acute Complications
- Seizures: 20-30% of bacterial meningitis cases
- Cerebral edema: Increased intracranial pressure, herniation risk
- Hydrocephalus: Communicating or obstructive forms
- SIADH: Syndrome of inappropriate antidiuretic hormone secretion
- Cerebral venous thrombosis: Particularly with severe inflammation
Long-term Sequelae and Follow-up
- Hearing loss: 10-30% of bacterial meningitis survivors
- Cognitive impairment: Memory, executive function deficits
- Motor deficits: Hemiparesis, ataxia, cranial nerve palsies
- Seizure disorders: Development of epilepsy post-meningitis
- Behavioral/psychiatric: Depression, anxiety, personality changes
⚠️ Public Health Alert: Meningococcal meningitis is a nationally notifiable disease - immediate notification of public health authorities is required for case management, contact tracing, and outbreak control. Timely reporting facilitates appropriate public health interventions.
🧠 Clinical Pearls
Essential considerations for meningitis recognition, management, and prevention:
- Bacterial meningitis is a true neurological emergency - time to antibiotics critically impacts outcomes
- The classic triad (fever, headache, neck stiffness) is present in only 45% of cases - maintain high index of suspicion
- Never delay antibiotics for imaging or lumbar puncture - administer immediately after blood cultures
- Empiric antimicrobial selection should be guided by age, risk factors, and local resistance patterns
- Add ampicillin for Listeria coverage in neonates, elderly (>50 years), and immunocompromised patients
- Dexamethasone reduces neurological sequelae in pneumococcal meningitis when given before/with antibiotics
- CSF analysis remains crucial for diagnosis and differentiation between meningitis types
- Chemoprophylaxis is indicated for close contacts of meningococcal meningitis cases
- Vaccination has dramatically reduced incidence of H. influenzae and pneumococcal meningitis
- Long-term follow-up for sequelae (hearing, cognitive, neurological) is essential for survivors
🔬 Pathology Study Tips:
- Master CSF interpretation: Differentiate bacterial, viral, TB, and fungal patterns
- Know age-specific pathogens: Neonates (GBS, E. coli, Listeria) vs adults (S. pneumoniae, N. meningitidis)
- Understand empiric therapy: Vancomycin + cephalosporin ± ampicillin based on risk factors
- Learn vaccination schedules: PCV, MenACWY, MenB, Hib timing and indications
- Recognize emergency signs: Purpuric rash, altered mental status, seizure, shock
🧭 Conclusion
Meningitis management represents one of the most time-critical challenges in infectious diseases and neurology, requiring rapid recognition, immediate antimicrobial therapy, and comprehensive supportive care. The significant reduction in meningitis incidence through vaccination programs stands as a major public health achievement, yet vigilance remains essential for early detection and management of cases. Modern meningitis care balances emergency intervention with attention to long-term neurological outcomes, emphasizing the importance of adjunctive therapies, complication management, and systematic follow-up. Healthcare providers must maintain a high index of suspicion for meningitis across all patient populations, particularly recognizing atypical presentations in vulnerable groups.
Clinical Wisdom: "In meningitis, minutes matter. When in doubt, treat - it's better to give antibiotics for ultimately proven viral meningitis than to delay treatment for bacterial meningitis. The consequences of missing bacterial meningitis far outweigh the risks of unnecessary antimicrobial therapy in suspicious cases."